Sangamo Therapeutics saw the highest growth of 149% in patent filings in February and 274% in grants in January in Q1 2024. Compared to Q4 2023, Q1 2024 saw an increase in patent filings by 85% and grants by 274%. GlobalData’s DataBook provides a comprehensive analysis of Sangamo Therapeutics‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Sangamo Therapeutics has been focused on protecting inventions in United States(US) with ten publications in Q1 2024

The United States(US) Patent Office dominates the patent filings and grants with nearly 31% filings and 20% grants. The United States(US), Japan(JP), Israel(IL), and China(CN) patent Office are among the top ten patent offices where Sangamo Therapeutics is filings its patents. Among the top granted patent authorities, Sangamo Therapeutics has 28% of its grants in Australia(AU), 20% in United States(US) and 16% in Israel(IL).

Massachusetts Institute of Technology and Broad Foundation could be the strongest competitors for Sangamo Therapeutics

In terms of grant share, Sangamo Therapeutics stands in fourth position among its competitors. Massachusetts Institute of Technology and Broad Foundation secured the top positions according to recent patent publication data.

Patents related to rare diseases and genomics lead Sangamo Therapeutics's portfolio

Sangamo Therapeutics has the highest number of patents in rare diseases followed by, genomics and cell & gene therapy. For rare diseases, nearly 56% of patents were filed and 38% of patents were granted in Q1 2024.

Alzheimer's disease related patents lead Sangamo Therapeutics portfolio followed by lysosomal storage disorder, and mucopolysaccharidosis

Sangamo Therapeutics has highest number of patents in alzheimer's disease followed by lysosomal storage disorder, mucopolysaccharidosis, mucopolysaccharidosis i (mps i) (hurler syndrome ), and mucopolysaccharidosis ii (mps ii) (hunter syndrome ). For alzheimer's disease, nearly 7% of patents were filed and 6% of patents were granted in Q1 2024.

For comprehensive analysis of Sangamo Therapeutics's filings and grants, buy the databook here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.